semaglutide indications Ozempic® (semaglutide) and Mounjaro™ (tirzepatide), a major breakthrough for the treatment of obesity Semaglutide: Double-edged Sword with Risks

What has surprised the medical community are the positive results in late-stage trials for sleep apnea, knee arthritis, and kidney disease

Kellerer, M., Kaltoft, M

A spokesperson for Eli Lilly, which produces Zepbound and Mounjaro, told The Independent that Zepbound and Mounjaro autoinjectors and Zepbound vials are approved for single-use onlydose-splitting or microdosing is not contemplated by the FDA-label and may pose patient safety risks. Novo Nordisk, which produces Ozempic and Wegovy, told The Independent the company "[does] not condone the misuse of our products." The company noted it is concerned about non-FDA approved knock-off versions of semaglutide and sources spreading misinformation about GLP-1s to the public. The FDA warns that using unapproved versions of GLP-1 drugs can be risky for patients. This story was updated on September 4, 2025 to include responses from Eli Lilly and Novo Nordisk Join our commenting forum Join thought-provoking conversations, follow other Independent readers and see their replies Comments

It would usually form in the legs, but it can occur in the arms or any other veins

Weight loss accelerates weeks 12-24 (fastest period)

Enhanced metabolic efficiency: Retatrutide may help the body shift towards using stored fat for energy more often, rather than depending solely on glucose